Benitec Biopharma Inc.
8.65USD
-0.1700 (-1.93%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on BNTC.
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | 75.0K | 0.0 | — | — | 0.0 | 0.0 |
| Q1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Q2 | 14.0K | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Q3 | 54.0K | 0.0 | 0.0 | 0.0 | — | — |
| Q4 | 7.0K* | 0.0* | — | — | — | — |
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | -.543 | -.610 | -1.05 | -.980 | -1.22 | -1.43 |
| Q1 | -.141 | -.169 | -.180 | -.220 | -.288 | — |
| Q2 | -.128 | -.189 | -.260 | -.260 | -.298 | — |
| Q3 | -.103 | -.115 | -.380 | -.240 | — | — |
| Q4 | -.129* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.129* |
| -.210 |
| -.275* |
| — |
| — |
Debt level and coverage